91 related articles for article (PubMed ID: 17592250)
1. Immune analysis on mtHSV mediated tumor therapy in HSV-1 seropositive mice.
Zhu H; Su Y; Zhou S; Xiao W; Ling W; Hu B; Liu Y; Qi Y
Cancer Biol Ther; 2007 May; 6(5):724-31. PubMed ID: 17592250
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for mice sarcoma with oncolytic herpes simplex virus-1 lacking the apoptosis-inhibiting gene, icp34.5.
Lan P; Dong C; Qi Y; Xiao G; Xue F
J Biochem Mol Biol; 2003 Jul; 36(4):379-86. PubMed ID: 12895296
[TBL] [Abstract][Full Text] [Related]
3. Tumor-targeted therapy with a conditionally replicating mutant of HSV-1 induces regression of xenografted human hepatomas.
Xue F; Dong CY; Su Y; Zhu H; Ling W; Liu Y; Xu H; Xiao W; Zhou S; Qi YP
Cancer Biol Ther; 2005 Nov; 4(11):1234-9. PubMed ID: 16357508
[TBL] [Abstract][Full Text] [Related]
4. Selectively oncolytic mutant of HSV-1 lyses HeLa cells mediated by Ras/RTN3.
Su Y; Zhu H; Xiao W; Xu Q; Zhu L; Zhang X; Wan Q; Zhou S; Du E; Xu H; Yao L; Lv S; Hu B; Liu Y; Qi Y
Cancer Biol Ther; 2007 Feb; 6(2):202-8. PubMed ID: 17218780
[TBL] [Abstract][Full Text] [Related]
5. Rasgrp2 regulates the permissiveness of NIH3T3 cells to a herpes simplex virus 1 mutant with inactivated ICP34.5 gene.
Xiao W; Su Y; Zhou S; Yi Ch; He G; Liu Y; Qi Y
Acta Virol; 2013; 57(1):41-9. PubMed ID: 23530823
[TBL] [Abstract][Full Text] [Related]
6. Folate-conjugated herpes simplex virus for retargeting to tumor cells.
Ye ZQ; Zou CL; Chen HB; Lv QY; Wu RQ; Gu DN
J Gene Med; 2020 Jul; 22(7):e3177. PubMed ID: 32096291
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
9. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.
Chahlavi A; Rabkin S; Todo T; Sundaresan P; Martuza R
Gene Ther; 1999 Oct; 6(10):1751-8. PubMed ID: 10516725
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer.
Okunaga S; Takasu A; Meshii N; Imai T; Hamada M; Iwai S; Yura Y
Cancer Gene Ther; 2015 Apr; 22(3):163-8. PubMed ID: 25656776
[TBL] [Abstract][Full Text] [Related]
12. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Todo T; Martuza RL; Rabkin SD; Johnson PA
Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
[TBL] [Abstract][Full Text] [Related]
14. Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.
Lambright ES; Kang EH; Force S; Lanuti M; Caparrelli D; Kaiser LR; Albelda SM; Molnar-Kimber KL
Mol Ther; 2000 Oct; 2(4):387-93. PubMed ID: 11020355
[TBL] [Abstract][Full Text] [Related]
15. Characterization of herpes simplex virus 1 strains as platforms for the development of oncolytic viruses against liver cancer.
Argnani R; Marconi P; Volpi I; Bolanos E; Carro E; Ried C; Santamaria E; Pourchet A; Epstein AL; Brocker T; Corrales FJ; Manservigi R; Goicoechea I; Foschini M; Hernandez-Alcoceba R
Liver Int; 2011 Nov; 31(10):1542-53. PubMed ID: 22093330
[TBL] [Abstract][Full Text] [Related]
16. Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes.
Osorio Y; Ghiasi H
J Virol; 2003 May; 77(10):5774-83. PubMed ID: 12719570
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
18. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
[TBL] [Abstract][Full Text] [Related]
19. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
20. Herpes virus entry mediator in human corneal epithelial cells modulates the production of inflammatory cytokines in response to HSV type 1 challenge.
Guo H; Pang K; Wei Y; Yi C; Wu X
Ophthalmic Res; 2015; 54(3):128-34. PubMed ID: 26328884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
